Inactivation of the Von Hippel-Lindau tumor suppressor gene ( VHL ) causes cancers of the kidney, brain and retina in humans. The VHL protein associates with Elongin B and Elongin C in a VBC complex. VHL was initially thought to inhibit transcription by sequestering Elongin B and C from the Elongin (SIII) complex, composed of Elongins A, B and C. However, the concentration of Elongin B and C is reported to be 100 to 1000-fold higher than that of VHL in cells (Conaway et al., 1998, BBA 1377: M49) making it unlikely that VHL can sequester them. Currently, how VHL functions to suppress tumor formation is unknown. Recently, VHL was found to bind to human CUL-2 (Pause et al., 1997, PNAS 94: 2155).
cul-2 is a member of the cullin gene family. Cullin homologs Cdc53 and CUL-1 are involved in the degradation of Cyclins and CKIs to regulate cell cycle progression. In
cul-2 (
ek1 ) mutants, germ cells are arrested in G1 phase, and this is correlated with a higher level of CKI-1, a member of the CIP/KIP family of cyclin-dependent kinase inhibitors. Our results suggest that
cul-2 is required for the G1 to S phase transition, potentially functioning by degrading CKI-1. Interestingly, overexpression of wild type VHL in human cells also induces a G1 phase cell cycle arrest and increases the level of the CKI
p27KIP1 (Kim et al., 1998, BBRC 253: 672). Based on these observations, we propose a model in which VHL negatively regulates CUL-2, which negatively regulates CKIs, which negatively regulates the cell cycle. Since a VHL homolog is present in C. elegans we are undertaking a genetic study of
cul-2 and vhl . Both the vhl (
ok161 ) allele and the
cul-2 (
ek1 ) allele were obtained by PCR screening for deletions in EMS mutagenized animals, by G.M./R.B. and E.T.K., respectively. We are trying to gain insights into the (potential) genetic interaction of vhl and
cul-2 by making a strain homozygous for vhl (
ok161 ) and heterozygous for
cul-2 (
ek1 ) and analyzing the resulting homozygous progeny. We are in the final stage of making this strain and we will present the double mutant phenotype at the meeting.